Defining benefits and risks for SERMs in clinical trials and clinical practice

Annals of the New York Academy of Sciences

Volumn 949, Issue , 2001, Pages 304-314

  Johnson, Susan R ^a,d   Dunn, Barbara K ^b   Anthony, Marietta ^c  

^a UNIVERSITY OF IOWA   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^d UNIVERSITY OF IOWA   (United States)

Author keywords

Benefit risk; Benefits; Clinically meaningful; Estrogen; SERMs; Statistically significant

Indexed keywords

ESTROGEN; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

BREAST CANCER; CANCER PREVENTION; CLINICAL PRACTICE; CLINICAL TRIAL; CONFERENCE PAPER; HEART PROTECTION; HUMAN; MEDICAL DECISION MAKING; MENOPAUSE; RISK BENEFIT ANALYSIS; STATISTICAL ANALYSIS;

EID: 0035683626     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2001.tb04037.x     Document Type: Conference Paper

References (29)

1. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually
2. Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer
3. Risk/benefit assessment of tamoxifen to prevent breast cancer - Still a work in progress?
4. American Society of Clinical Oncology technology assessment on breast cancer risk reduction strategies: Tamoxifen and raloxifene
5. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study
6. The Breast Cancer Prevention Trial and the woman at high risk for breast cancer
7. Prevention of breast cancer
8. Clinical effects of a standardized soy extract in postmenopausal women: A pilot study
9. Soy isoflavones: Are they useful in menopause?
10. Baseline characteristics of participants in the antihypertensive lipid-lowering treatment to prevent heart attack trial (ALLHAT)
11. Major cardiovascular events in hypertensive patients randomized to doxazosin vs. chlorthalidone: The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT)
12. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women
13. Effects of estrogen replacement on the progression of coronary-artery atherosclerosis
14. Hormone replacement therapy and cardiovascular disease: A statement for health care professionals from the American Heart Association
15. Users' guides to the medical literature: XX. Integrating research evidence with the care of the individual patient - Evidence-Based Medicine Working Group
16. Users' guides to the medical literature: XXI. Using electronic health information resources in evidence-based practice - Evidence-Based Medicine Working Group
17. Users' guides to the medical literature: XIX. Applying clinical trial results. A. How to use an article measuring the effect of an intervention on surrogate endpoints - Evidence-Based Medicine Working Group
18. Users' guides to the medical literature: XVI. How to use a treatment recommendation - Evidence-Based Medicine Working Group and the Cochrane Applicability Methods Working Group
19. Prior and current health characteristics of postmenopausal estrogen replacement therapy users compared with nonusers
20. The physician's role in women's decision making about hormone replacement therapy
21. Randomized trial of a portable, self-administered decision aid for postmenopausal women considering long-term preventive hormone therapy
22. Decision aids for patients facing health treatment or screening decisions: Systematic review
23. The effect of raloxifene on risk of breast cancer in postmenopausal women: Results from the MORE randomized trial - Multiple Outcomes of Raloxifene Evaluation
24. Patient-identified needs for hormone replacement therapy counseling: A qualitative study
25. Individualizing therapy to prevent long-term consequences of estrogen deficiency in postmenopausal women
26. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)